Stock Quote

BioSpecifics Technologies Corp. Appoints Gerald E. Bendele to Board of Directors

Oct 30, 2002

BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that Gerald E. Bendele has been appointed to its Board of Directors.

(Logo: )

Mr. Bendele served as BASF Group Vice President Chemical Intermediates from 1995 to his retirement this year. Prior to that position, Mr. Bendele had been President of BASF's pharmaceutical business in the U.S., Knoll Pharmaceutical Company, since 1989. Mr. Bendele joined Knoll Pharmaceuticals as a sales representative in 1966. After several years' experience as a Sales Representative and Division Manager, he moved to Whippany, New Jersey to accept the position of National Sales Manager in 1977. He was appointed Director of Marketing in 1979 and Vice President of Marketing in 1982. Prior to his appointment to President, he served as Senior Vice President, Pharmaceuticals with responsibilities including Marketing/Sales, Medical Affairs and Production. Knoll Pharmaceuticals was sold to Abbott Laboratories in 2001.

Edwin H. Wegman, BioSpecifics Chairman and President: "We are very fortunate to have Gerald join our Board of Directors. His broad based understanding of the pharmaceutical industry, and of our product, Collagenase Santyl® Ointment will be of great value to BioSpecifics. I have had the privilege of working with Gerald since he became President of Knoll and find his acumen and judgment outstanding. His guidance will be particularly helpful now as we move in the direction of forming strategic alliances for second generation collagenase products in development, such as Cordase™ for the treatment of Dupuytren's disease and Plaquase™ for the treatment of Peyronie's disease."

BioSpecifics Technologies Corp. is a biopharmaceutical company with a focus on wound healing and tissue remodeling. It has pioneered the application of Collagenase for several disease conditions, notably dermal ulcers, pressure sores (bedsores), and second and third degree burns. BioSpecifics produces Collagenase ABC, the essential ingredient in the prescription drug Collagenase Santyl® Ointment sold in the United States, and under other trademarks abroad. BioSpecifics is also developing an injectable form of its enzyme. Phase 2 clinical trials are completed in the U.S. for the use of this injectable collagenase in treating Dupuytren's disease, which restricts the extension of one or more fingers. In addition, clinical trials investigating the use of injectable collagenase in the treatment of lipoma reduction have been initiated. Clinical and laboratory investigations further profiling the potential role of collagenase and its pharmacological activity for wound healing are being pursued.

  Santyl® is a registered trademark of Abbott Laboratories (NYSE: ABT).

                      Visit BioSpecifics' website at
           its Dupuytren's Disease patient discussion forum at
          and its Peyronie's Disease patient discussion forum at

Forward-looking statements in this release involve a number of risks and uncertainties including, but not limited to, government regulation, the ability of the Company to obtain approval of its production facilities and adequately address concerns of the FDA, liquidity, product demand, pricing, market acceptance, changing economic conditions, risks in product and technology development, the effect of the Company's accounting policies, and other risk factors detailed in the Company's filings with the Securities and Exchange Commission.

Make Your Opinion Count - Click Here


SOURCE: BioSpecifics Technologies Corp.

CONTACT: Thomas L. Wegman of BioSpecifics Technologies Corp.,

Web site: